This dispatch covers BPC-157: A Comprehensive Review of Its Therapeutic Potential in the Healing research category, authored by Chen, J., Williams, R., Patel, S., originally published in Journal of Peptide Research on March 15, 2024. It has been cited 156 times and takes approximately 12 minutes to read. The Peptide Dispatch curates peer-reviewed peptide research for self-directed learners. All summaries are presented for Research Use Only and do not constitute medical advice.
BPC-157 is the most-studied peptide in the regenerative-medicine preclinical literature, with over fifty rodent and in-vitro studies converging on three main mechanisms: nitric-oxide system modulation, upregulation of growth-factor receptors (VEGF-R2, FGF, EGF) in healing tissue, and direct gastrointestinal cytoprotection. Reported effects span tendon repair, GI ulcer healing, anti-colitis activity, and CNS-injury attenuation. The review highlights that despite the consistency of preclinical findings, no Phase 2 or Phase 3 human trials have been published, dosing protocols vary widely across labs, and most work comes from a small handful of research groups. Pharmacokinetics in humans remain uncharacterised. Safety signals in animal models are reassuring within tested ranges but long-term carcinogenicity, reproductive, and immunogenicity data are absent. The peptide is unscheduled by the FDA and is not legally compounded by US pharmacies following the 2023 categorisation update. Researchers planning further work should prioritise standardised dosing, independent replication, and properly powered placebo-controlled human trials in well-defined indications such as recalcitrant tendinopathy.
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a fragment of human gastric juice protein. Across more than two decades of preclinical investigation, it has emerged as one of the most extensively studied peptides in the regenerative-medicine research literature. This systematic review synthesises findings from over fifty published preclinical studies — predominantly rodent models, with a smaller number of in-vitro mechanistic experiments — and evaluates the consistency, biological plausibility, and translational implications of the reported effects. The peptide has been investigated in models of tendon and ligament injury, muscle crush trauma, gastrointestinal ulceration, inflammatory bowel disease, post-surgical anastomosis healing, central-nervous-system injury, and vascular dysfunction. The convergence of effects across such diverse tissue systems is itself notable and has driven interest in BPC-157 as a potential candidate for translational research. Mechanistically, the most consistently reported pathway involves modulation of the nitric-oxide (NO) system. Multiple research groups have demonstrated that BPC-157 administration influences endothelial NO synthase activity, restores impaired NO-mediated vasodilation in injured tissue, and accelerates angiogenic responses measured by capillary density and CD31-positive vessel counts in healing wound beds. A second well-characterised pathway involves growth-factor receptor expression: preclinical data suggest BPC-157 upregulates VEGF-receptor 2, FGF, and EGF in tendon fibroblasts and tenocytes, contributing to the accelerated tendon-to-bone healing observed in transected Achilles and rotator-cuff models. A third pathway relates to gastrointestinal cytoprotection. The earliest BPC-157 work, conducted in the 1990s in models of gastric and duodenal ulceration, showed that the peptide prevents NSAID-induced mucosal damage, reduces lesion area in alcohol-induced gastric injury, and acce…
All information is presented for Research Use Only (RUO). Not medical advice.